Skip to content

Clinical trials

Terminated Phase 2 Myelodysplastic Syndromes trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myelodysplastic Syndromes Phase: Phase 2 Status: Terminated Clear all

130 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20013
20022
20047
20057
200613
20078
20087
200912
20109
20116
20126
20133
20144
20157
20166
20178
20182
20194
20214
20227
20232

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated130

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center13
Fred Hutchinson Cancer Center9
Masonic Cancer Center, University of Minnesota8
Novartis Pharmaceuticals5
H. Lee Moffitt Cancer Center and Research Institute3
Massachusetts General Hospital3
St. Jude Children's Research Hospital3
Wake Forest University Health Sciences3
Weill Medical College of Cornell University3
Case Comprehensive Cancer Center2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myelodysplastic Syndromes130
Leukemia, Myeloid, Acute52
Leukemia45
Precursor Cell Lymphoblastic Leukemia-Lymphoma29
Multiple Myeloma25
Leukemia, Lymphocytic, Chronic, B-Cell23
Lymphoma23
Leukemia, Myelogenous, Chronic, BCR-ABL Positive21
Lymphoma, Non-Hodgkin21
Hodgkin Disease20

Trials

Showing 1 to 25 of 130. Each trial links to its page on Pharma Observatory.

30 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.